miCure Therapeutics acquired key oligonucleodites patents fron nLife Therapeutics


miCure Therapeutics is a leading-edge biotech company focused on micro-RNA therapeutics and diagnostics for the central nervous system. Current development program based on mir135 mimic as a therapeutic agent for a long term management of Treatment Resistant Depressive patients (TRD patients). Oligonucleotide delivery solutions developed by nLife Therapeutics reinforces this program by reducing the effective dose, increasing the safety and facilitating the delivery to the brain by intranasal administration (nose-to-brain).

miCure acquired a key oligonucleotide patent family from nLife Therapeutics, S.L. This new technology allows miCure to conjugate small molecules to micro-RNAs for cell specific delivery in the brain. The small molecule component binds to a specific neurotransmitter transporter located in the cellular surface of the neuron and promotes the selective delivery of the therapeutic micro-RNA.

The new patent family protects current mir135 candidates under development and extend the pipeline potential to other brain disorders treatments like: Parkinson, Alzheimer, schizophrenia, cognitive and memory disorders, obsessive-compulsive disorder (OCD), pervasive developmental disorder (PDD), post-traumatic stress disorder (PTSD), anxiety disorder, bipolar disorder, eating disorder and chronic pain.